Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma (Q44908377)

7 December 2017

title

Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma (English)

1 reference

7 December 2017

2

Atsushi Ohtsu

1 reference

7 December 2017

1

Kuniaki Shirao

1 reference

7 December 2017

Hideho Takada

3

1 reference

7 December 2017

Yasushi Mitachi

4

1 reference

7 December 2017

Kosei Hirakawa

5

1 reference

7 December 2017

Noboru Horikoshi

6

1 reference

7 December 2017

Takeshi Okamura

7

1 reference

7 December 2017

Koichi Hirata

8

1 reference

7 December 2017

Soh Saitoh

9

1 reference

7 December 2017

Hiroharu Isomoto

10

1 reference

7 December 2017

Atsushi Satoh

11

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

100

1 reference

7 December 2017

issue

11

1 reference

7 December 2017

page(s)

2355-2361

1 reference

Can eniluracil improve 5-fluorouracil therapy?

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Oral chemotherapy: rationale and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20277

7 January 2021

Identifiers

DOI

10.1002/CNCR.20277

1 reference

7 December 2017

1 reference